Longboard Pharmaceuticals
A clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $2.6b Valuation: $2.6b | Acquisition | |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to creating transformative medicines for neurological diseases, with a particular focus on rare conditions. The company leverages over 20 years of research in G protein-coupled receptors (GPCRs) to develop next-generation treatments. Longboard's pipeline includes innovative compounds like bexicaserin, aimed at treating seizures associated with Developmental and Epileptic Encephalopathies (DEEs), a group of severe epilepsies characterized by drug-resistant seizures and significant developmental delays. The company operates in the biopharmaceutical market, targeting healthcare providers and patients affected by neurological and rare diseases. Longboard's business model involves advancing its drug candidates through clinical trials, securing regulatory approvals, and eventually commercializing these therapies. Revenue is generated through partnerships, licensing agreements, and future product sales.
Keywords: GPCR research, neurological diseases, rare diseases, clinical-stage, biopharmaceutical, transformative medicines, DEEs, seizures, drug-resistant, developmental delays.